ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
BerGenBio and Merck to evaluate BGB324 with Keytruda in NSCLC and breast cancer
March 13, 2017Norwegian-based biopharmaceutical company BerGenBio has signed an agreement to clinically evaluate its lead candidate BGB324 with Merck’s Keytruda (pembrolizumab) in patients with advanced non-small-cell lung cancer (NSCLC) and triple-negative breast canc
Pharma Sources Insight January 2025
